NASDAQ$VYNE
VYNE Therapeutics INC · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Menlo Therapeutics reported fourth quarter and full year 2019 financial results, highlighting a net loss for Q4 and approval of the merger with Foamix.
Menlo Therapeutics reported a net loss of $21.5 million for the fourth quarter of 2019, compared to a net loss of $17.6 million for the same period in 2018. The company's shareholders approved the merger with Foamix, expected to close on or about March 9, 2020.
- Merger with Foamix was approved by shareholders of both companies.
- The combined company will focus on dermatology therapeutics.
- Menlo reported a net loss of $21.5 million for Q4 2019.
- Phase 3 clinical trial results for serlopitant expected in March or April 2020.
Headline financials
Revenue & EPS history
VYNE · Revenue · Quarterly
$86K
Revenue by segment
VYNE · $86K total across 1 segment · Q1 2026
- Royalty revenues$86K—100.0%
Forward guidance
Menlo is anticipating several key catalysts in the near term, including clinical trial results and regulatory action dates, but also faces risks related to the merger and ongoing clinical trials.
Tailwinds
- Phase 3 clinical trial results for serlopitant in prurigo nodularis expected in March or April 2020
- PDUFA action date of June 2, 2020 for FMX103 for rosacea treatment
- Phase 2 clinical trial results for FCD105 for acne treatment expected in Q2 2020
- New Drug Application submission for serlopitant for pruritus in prurigo nodularis expected in the second half of 2020 (assuming successful Phase 3 trials)
- Upcoming merger with Foamix
Headwinds
- Conditions to the closing of the merger may not be satisfied
- The merger may involve unexpected costs, liabilities or delays
- Menlo or Foamix may be adversely affected by other economic, business, and/or competitive factors
- The outcome of any legal proceedings related to the merger
- Risks relating to the planned merger with Foamix and risks resulting from the unpredictability of the regulatory process and regulatory developments in the United States and foreign countries.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2019
-1.0%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-13.3%
Avg return
30 days after
52%
17 / 33 earnings
Positive
+23.0%
Q4 2021
Best reaction
-38.4%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2025 | +1.0% | -0.2% | -0.5% | |
| Q2 2025 | +0.6% | -4.3% | -10.6% | |
| Q1 2025 | -2.4% | -20.0% | -28.1% | |
| Q4 2024 | -2.5% | -21.3% | -34.7% | |
| Q3 2024 | +1.0% | -4.2% | -14.4% | |
| Q2 2024 | +8.8% | +8.2% | +7.6% | |
| Q1 2024 | -1.8% | +6.3% | -17.3% | |
| Q4 2023 | -4.7% | -3.4% | +31.8% | |
| Q3 2023 | +1.7% | +11.4% | -23.1% | |
| Q2 2023 | -11.8% | -13.7% | -26.7% | |
| Q1 2023 | +20.9% | +17.9% | -11.9% | |
| Q4 2022 | -14.7% | -21.2% | -11.1% | |
| Q3 2022 | +9.7% | +0.0% | -15.4% | |
| Q2 2022 | +5.3% | +12.5% | -4.6% | |
| Q1 2022 | +5.0% | +8.2% | +27.2% | |
| Q4 2021 | +23.0% | +28.7% | -8.0% | |
| Q3 2021 | -1.5% | -5.9% | +10.3% | |
| Q2 2021 | -38.4% | -42.9% | -45.7% | |
| Q1 2021 | -19.7% | -24.8% | -95.3% | |
| Q4 2020 | -9.7% | -6.5% | -6.5% | |
| Q3 2020 | -2.6% | +0.6% | -1.2% | |
| Q2 2020 | -12.5% | -12.2% | -26.8% | |
| Q1 2020 | -7.2% | -13.3% | +7.2% | |
| Q4 2019 | +5.8% | +42.6% | -9.3% | |
| Q3 2019 | +4.4% | +2.6% | -21.3% | |
| Q2 2019 | -8.7% | -16.4% | +29.8% | |
| Q1 2019 | -1.3% | -2.3% | -4.5% | |
| Q4 2018 | +0.5% | +0.2% | -7.3% | |
| Q3 2018 | +1.7% | +0.0% | -17.8% | |
| Q2 2018 | +3.4% | -2.7% | -5.9% | |
| Q1 2018 | +9.2% | +7.2% | -11.9% | |
| Q4 2017 | +4.8% | +2.9% | -78.1% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro